Preparation and evaluation of immune effect of recombinant S1 protein based on SARS-CoV-2 beta variant
10.16303/j.cnki.1005-4545.2024.06.07
- VernacularTitle:新型冠状病毒Beta变异株S1重组蛋白的制备及免疫效果评价
- Author:
Zechang FAN
1
,
2
;
Sheng FENG
;
Mingzheng LIANG
;
Shanshan MA
;
Ningyi JIN
;
Zhuo HA
;
Huijun LU
Author Information
1. 吉林农业大学动物医学院,吉林长春 130118
2. 中国农业科学院长春兽医研究所,吉林长春 130122
- Keywords:
SARS-CoV-2;
beta variant;
Chinese hamster ovary cells;
recombinant protein;
immuno-genicity
- From:
Chinese Journal of Veterinary Science
2024;44(6):1133-1139
- CountryChina
- Language:Chinese
-
Abstract:
The codon sequence of the S1 protein of the SARS-CoV-2 Beta variant was optimized ac-cording to the preference of CHO cells and cloned into pSN expression vector to construct the re-combinant plasmid pSN-Beta-sl.Recombinant protein was expressed in CHO cells,identified using SDS-PAGE and Western blot,and purified through affinity chromatography.BALB/c mice were immunized with purified recombinant protein Beta-S1 combined with aluminum hydroxide adju-vant.Specific IgG antibody and its subtypes in serum and the cross-neutralization antibody activity against SARS-CoV-2 variants were evaluated.The results showed that the recombinant plasmid pSN-Beta-S1 was successfully constructed,and the recombinant protein Beta-S1 was produced u-sing the CHO cell expression system.The purified recombinant protein had a single band of about 120 kDa with the purity exceeding 85％and can bind to RBD pAb and strep-tag mAb.The recom-binant S1 protein showed good immunogenicity in BALB/c mice.The titers of specific IgG antibodies against RBD protein and S1 protein reached 1∶66 260 and 1∶133 120 on average 21 d after the third immunization,the antibody subtypes were mainly inclined to IgG1.Serum neutrali-zing antibody titer was 1∶629 for wild type,1∶1 720 for Beta,1∶374 for Delta,1∶77 for Omi-cron BA1 and 1∶101 for Omicron BA2.In this study,S1 recombinant protein of SARS-CoV-2 Beta variant was successfully expressed in CHO cell expression system and produced good immunoge-nicity and cross-neutralizing activity in BALB/c mice.These results provide a reference for the fur-ther development of broad-spectrum SARS-CoV-2 vaccine.
